85 related articles for article (PubMed ID: 7645964)
1. Heterogeneity in p53 mutations in mouse mammary tumor subpopulations with different metastatic potential from the orthotopic site.
Shekhar PV; Werdell J; Christman JK; Miller FR
Anticancer Res; 1995; 15(3):815-20. PubMed ID: 7645964
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
3. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
4. Latent expression of p53 mutations and radiation-induced mammary cancer.
Selvanayagam CS; Davis CM; Cornforth MN; Ullrich RL
Cancer Res; 1995 Aug; 55(15):3310-7. PubMed ID: 7614466
[TBL] [Abstract][Full Text] [Related]
5. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability.
Miller FR; Miller BE; Heppner GH
Invasion Metastasis; 1983; 3(1):22-31. PubMed ID: 6677618
[TBL] [Abstract][Full Text] [Related]
6. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells.
Ridgeway AG; McMenamin J; Leder P
Oncogene; 2006 Jun; 25(25):3518-27. PubMed ID: 16434961
[TBL] [Abstract][Full Text] [Related]
7. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
8. Infrequent p53 mutation in mouse tumors with deregulated myc.
Gutierrez MI; Bhatia K; Siwarski D; Wolff L; Magrath IT; Mushinski JF; Huppi K
Cancer Res; 1992 Feb; 52(4):1032-5. PubMed ID: 1737333
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
10. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
[TBL] [Abstract][Full Text] [Related]
11. Characterization of p53 gene mutations in colorectal carcinomas from an Asian population.
Shi CY; Phang TW; Ngoi SS; Wee A; Li B; Lin Y; Lee HP; Ong CN
Anticancer Res; 1994; 14(6B):2811-6. PubMed ID: 7872723
[TBL] [Abstract][Full Text] [Related]
12. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice.
Zhuang SM; Wiseman RW; Söderkvist P
Oncogene; 2002 Aug; 21(36):5643-8. PubMed ID: 12165863
[TBL] [Abstract][Full Text] [Related]
13. p53 expression, mutation, and allelic deletion in ovarian cancer.
McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
[TBL] [Abstract][Full Text] [Related]
14. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation.
Shibata MA; Akao Y; Shibata E; Nozawa Y; Ito T; Mishima S; Morimoto J; Otsuki Y
Cancer Chemother Pharmacol; 2007 Oct; 60(5):681-91. PubMed ID: 17256131
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation.
Ricevuto E; Ficorella C; Fusco C; Cannita K; Tessitore A; Toniato E; Gabriele A; Frati L; Marchetti P; Gulino A; Martinotti S
Am J Pathol; 1996 Feb; 148(2):405-13. PubMed ID: 8579104
[TBL] [Abstract][Full Text] [Related]
18. p53 gene mutation spectrum in human unknown primary tumors.
Bar-Eli M; Abbruzzese JL; Lee-Jackson D; Frost P
Anticancer Res; 1993; 13(5A):1619-23. PubMed ID: 8239543
[TBL] [Abstract][Full Text] [Related]
19. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR
Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250
[TBL] [Abstract][Full Text] [Related]
20. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
